These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

759 related articles for article (PubMed ID: 27413037)

  • 1. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.
    Florea VG; Rector TS; Anand IS; Cohn JN
    Circ Heart Fail; 2016 Jul; 9(7):. PubMed ID: 27413037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
    Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction.
    Park CS; Park JJ; Mebazaa A; Oh IY; Park HA; Cho HJ; Lee HY; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
    J Am Heart Assoc; 2019 Mar; 8(6):e011077. PubMed ID: 30845873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial.
    Desai AS; Vaduganathan M; Cleland JG; Claggett BL; Barkoudah E; Finn P; McCausland FR; Yilmaz MB; Lefkowitz M; Shi V; Pfeffer MA; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Dec; 14(12):e008597. PubMed ID: 34807713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
    Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ; Cohen-Solal A; Böhm M; Anker SD; Babalis D; Roughton M; Coats AJ; Poole-Wilson PA; Flather MD;
    J Am Coll Cardiol; 2009 Jun; 53(23):2150-8. PubMed ID: 19497441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
    Villani A; Ravaro S; Cerea P; Caravita S; Ciambellotti F; Branzi G; Munforti C; Parati G; Malfatto G
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):682-687. PubMed ID: 32744827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
    Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
    Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
    Wong M; Staszewsky L; Latini R; Barlera S; Volpi A; Chiang YT; Benza RL; Gottlieb SO; Kleemann TD; Rosconi F; Vandervoort PM; Cohn JN;
    J Am Coll Cardiol; 2002 Sep; 40(5):970-5. PubMed ID: 12225725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
    Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
    Ter Arkh; 2006; 78(9):61-71. PubMed ID: 17076227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
    Zile MR; Jhund PS; Baicu CF; Claggett BL; Pieske B; Voors AA; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
    Circ Heart Fail; 2016 Jan; 9(1):. PubMed ID: 26754625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left-Ventricular Function After 3 Months of Sacubitril-Valsartan in Acute Decompensated Heart Failure.
    Mirić D; Baković D; Eterović D; Sorić T; Čapkun V; Vuković I; Duplančić D; Barac A
    J Cardiovasc Transl Res; 2021 Apr; 14(2):290-298. PubMed ID: 32557158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MY APPROACH to the patient with heart failure and improved ejection fraction
    Cohn JN
    Trends Cardiovasc Med; 2018 Feb; 28(2):153. PubMed ID: 29032935
    [No Abstract]   [Full Text] [Related]  

  • 14. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
    Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
    Ter Arkh; 2006; 78(8):14-20. PubMed ID: 17078211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy.
    Shen L; Ramires F; Martinez F; Bodanese LC; Echeverría LE; Gómez EA; Abraham WT; Dickstein K; Køber L; Packer M; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Jhund PS; Gimpelewicz CR; McMurray JJV;
    Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29141857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial.
    Park K; Park TH
    Trials; 2016 Nov; 17(1):530. PubMed ID: 27809882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotyping Heart Failure According to the Longitudinal Ejection Fraction Change: Myocardial Strain, Predictors, and Outcomes.
    Park JJ; Mebazaa A; Hwang IC; Park JB; Park JH; Cho GY
    J Am Heart Assoc; 2020 Jun; 9(12):e015009. PubMed ID: 32519555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valsartan for the treatment of heart failure.
    Latini R; Masson S; Staszewsky L; Maggioni AP
    Expert Opin Pharmacother; 2004 Jan; 5(1):181-93. PubMed ID: 14680446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological therapy of heart failure with reduced ejection fraction].
    Wieser M; Rhyner D; Martinelli M; Suter T; Schnegg B; Bösch C; Wigger O; Dobner S; Hunziker L
    Ther Umsch; 2018 Sep; 75(3):180-186. PubMed ID: 30145973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.